Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this meta-analysis indicates that FGFR2 overexpression is associated with poor pathological features and prognosis in patients with GC.
|
30662521 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification of fibroblast growth factor receptor2 (FGFR2) has been regarded as a druggable target in gastric cancer (GC).
|
30044964 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer.
|
29786108 |
2018 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 was shown to be markedly overexpressed in GC tissues and was correlated with a high risk of lymph node metastasis, late clinical stage, and poor prognosis.
|
30355943 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, targeting FGFR2 has drawn attention as a form of gastric cancer therapy, and FGFR-selective inhibitors have shown promising efficacy in clinical studies.
|
30045926 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer.
|
28852882 |
2018 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There was no interaction between FGFR2 expression and patient survival outcomes in stage II/III gastric cancer.
|
29434882 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments.
|
29876827 |
2018 |
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the current study, we aimed at revealing the function of DDX6 in HER2 and FGFR2 related human gastric cancer (GC) by using clinical samples and GC cell lines.
|
29987267 |
2018 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer.
|
28629429 |
2017 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
|
28122360 |
2017 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
|
28002800 |
2017 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer.
|
28618942 |
2017 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that FGFR2 amplification is a relevant therapeutic target in GC with peritoneal carcinomatosis.
|
28501555 |
2017 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy.
|
27802183 |
2017 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
|
27230412 |
2016 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription.
|
27107424 |
2016 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach.
|
27197184 |
2016 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
|
26516773 |
2015 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
|
25972329 |
2015 |